SAFETY AND EFFICACY OF UPADACITINIB FOR PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, PHASE 1 TRIAL

被引:4
|
作者
Brunner, H. [1 ]
Horneff, G. [2 ,3 ]
Foeldvari, I. [4 ]
Anton, J. [5 ]
Mohamed, M. E. [6 ]
Qian, Y. [6 ]
Unnebrink, K. [7 ]
Hao, S. [6 ]
Camp, H. [6 ]
Khan, N. [6 ]
Shmagel, A. [6 ]
机构
[1] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Rheumatol, Cincinnati, OH USA
[2] Asklepios Clin Sankt Augustin, Gen Pediat, St Augustin, Germany
[3] Univ Hosp Cologne, Paediat & Adolescents Med, Cologne, Germany
[4] Klinikum Eilbek, Hamburger Zentrum Kinder & Jugendrheumatol, Hamburg, Germany
[5] Univ Barcelona, Hosp Sant Joan Deu, Pediat Rheumatol, Barcelona, Spain
[6] AbbVie, Rheumatol, N Chicago, IL USA
[7] AbbVie Deutschland GmbH & Co KG, Rheumatol, Ludwigshafen, Germany
关键词
Clinical Trials; Safety; Outcome measures;
D O I
10.1136/annrheumdis-2023-eular.3987
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:108 / 109
页数:2
相关论文
共 50 条
  • [21] Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
    Brunner, Hermine I.
    Ruperto, Nicolino
    Zuber, Zbigniew
    Keane, Caroline
    Harari, Olivier
    Kenwright, Andrew
    Lu, Peng
    Cuttica, Ruben
    Keltsev, Vladimir
    Xavier, Ricardo M.
    Calvo, Inmaculada
    Nikishina, Irina
    Rubio-Perez, Nadina
    Alexeeva, Ekaterina
    Chasnyk, Vyacheslav
    Horneff, Gerd
    Opoka-Winiarska, Violetta
    Quartier, Pierre
    Silva, Clovis A.
    Silverman, Earl
    Spindler, Alberto
    Baildam, Eileen
    Luz Gamir, M.
    Martin, Alan
    Rietschel, Christoph
    Siri, Daniel
    Smolewska, Elzbieta
    Lovell, Daniel
    Martini, Alberto
    De Benedetti, Fabrizio
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1110 - 1117
  • [22] Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results
    Brunner, Hermine I.
    Nanda, Kabita
    Toth, Mary
    Foeldvari, Ivan
    Bohnsack, John
    Milojevic, Diana
    Rabinovich, C. Egla
    Kingsbury, Daniel J.
    Marzan, Katherine
    Chalom, Elizabeth
    Horneff, Gerd
    Kuester, Rolf-Michael
    Dare, Jason A.
    Trachana, Maria
    Jung, Lawrence K.
    Olson, Judyann
    Minden, Kirsten
    Quartier, Pierre
    Bereswill, Mareike
    Kalabic, Jasmina
    Kupper, Hartmut
    Lovell, Daniel J.
    Martini, Alberto
    Ruperto, Nicolino
    ARTHRITIS CARE & RESEARCH, 2020, 72 (10) : 1420 - 1430
  • [23] Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
    Alexeeva, Ekaterina
    Dvoryakovskaya, Tatiana
    Zholobova, Elena
    Krekhova, Elizaveta
    Raupov, Rinat
    Bukhanova, Daria
    Egorova, Alina
    Kuzkina, Sofia
    Samsonov, Mikhail
    Nikishina, Irina
    Kostik, Mikhail
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 808 - 810
  • [24] Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
    OU Loskutova (Konopelko)
    ES Zholobova
    MN Nikolaeva
    LA Galstian
    Pediatric Rheumatology, 12 (Suppl 1)
  • [25] A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis).
    Wajdula, J
    Pedersen, R
    Sanda, M
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S229 - S229
  • [26] A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis).
    Willis, RF
    Pedersen, R
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 101 - 101
  • [27] Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients
    Nishimura, Kenichi
    Hara, Ryoki
    Umebayashi, Hiroaki
    Takei, Syuji
    Iwata, Naomi
    Imagawa, Tomoyuki
    Shimizu, Masaki
    Tomiita, Minako
    Seko, Noriko
    Kitawaki, Tetsuji
    Yokota, Shumpei
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 226 - 234
  • [28] Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset
    Imagawa, T.
    Ozawa, R.
    Miyamae, T.
    Mori, M.
    Nerome, Y.
    Imanaka, H.
    Takei, S.
    Kawano, Y.
    Iwata, N.
    Miyoshi, M.
    Murata, T.
    Nishimoto, N.
    Kishimoto, T.
    Yokota, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 550 - 550
  • [29] Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension
    Ruperto, Nicolino
    Lovell, Daniel J.
    Cuttica, Ruben
    Woo, Patricia
    Meiorin, Silvia
    Wouters, Carine
    Silverman, Earl D.
    Balogh, Zsolt
    Henrickson, Michael
    Davidson, Joyce
    Foeldvari, Ivan
    Imundo, Lisa
    Simonini, Gabriele
    Oppermann, Joachim
    Xu, Stephen
    Shen, Yaung-Kaung
    Visvanathan, Sudha
    Fasanmade, Adedigbo
    Mendelsohn, Alan
    Martini, Alberto
    Giannini, Edward H.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (04) : 718 - 722
  • [30] Long-term efficacy & safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an open-label treatment extension.
    Lovell, D. J.
    Ruperto, N.
    Cuttica, R.
    Woo, P.
    Espada, G.
    Wouters, C.
    Silverman, E. D.
    Balogh, Z.
    Henrickson, M.
    Davidson, J.
    Foeldvari, I.
    Imundo, L.
    Simonini, G.
    Oppermann, J.
    Shen, Y. K.
    Visvanathan, S.
    Fasanmade, A.
    Mendelsohn, A.
    Giannini, E. H.
    Martini, A.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S632 - S632